PT87933B - Processo para a preparacao de di-hidrato de azitromicina - Google Patents
Processo para a preparacao de di-hidrato de azitromicina Download PDFInfo
- Publication number
- PT87933B PT87933B PT87933A PT8793388A PT87933B PT 87933 B PT87933 B PT 87933B PT 87933 A PT87933 A PT 87933A PT 8793388 A PT8793388 A PT 8793388A PT 87933 B PT87933 B PT 87933B
- Authority
- PT
- Portugal
- Prior art keywords
- dihydrate
- azithromycin
- water
- preparation
- water content
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 10
- -1 AZITHROMYCINE DIHYDRATE Chemical class 0.000 title 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims abstract description 16
- 229960004099 azithromycin Drugs 0.000 claims abstract description 13
- 150000004683 dihydrates Chemical class 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- 239000004215 Carbon black (E152) Substances 0.000 claims description 12
- 229930195733 hydrocarbon Natural products 0.000 claims description 12
- 150000002430 hydrocarbons Chemical class 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 150000004682 monohydrates Chemical class 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 description 3
- 229930006677 Erythromycin A Natural products 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960004924 azithromycin dihydrate Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- ZJULYDCRWUEPTK-UHFFFAOYSA-N dichloromethyl Chemical compound Cl[CH]Cl ZJULYDCRWUEPTK-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HQUPLSLYZHKKQT-WVVFQGGUSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-o Chemical compound O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HQUPLSLYZHKKQT-WVVFQGGUSA-N 0.000 description 1
- HRKNNHYKWGYTEN-HOQMJRDDSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)NC[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HRKNNHYKWGYTEN-HOQMJRDDSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229960003256 azithromycin monohydrate Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1987/001612 WO1989000576A1 (en) | 1987-07-09 | 1987-07-09 | Azithromycin dihydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT87933A PT87933A (pt) | 1989-06-30 |
| PT87933B true PT87933B (pt) | 1994-09-30 |
Family
ID=22202456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT87933A PT87933B (pt) | 1987-07-09 | 1988-07-07 | Processo para a preparacao de di-hidrato de azitromicina |
Country Status (45)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020231A2 (en) * | 2002-03-18 | 2003-12-31 | Pliva D D | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A |
| US5912331A (en) * | 1991-03-15 | 1999-06-15 | Merck & Co., Inc. | Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A |
| US5985844A (en) * | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
| US5189159A (en) * | 1992-04-02 | 1993-02-23 | Merck & Co., Inc. | 8a-AZA-8a-homoerythromycin cyclic iminoethers |
| CA2081268A1 (en) * | 1991-10-25 | 1993-04-26 | Katsuhiro Imaki | Glycine derivative monosodium salt tetrahydrate |
| US5215980A (en) * | 1992-01-17 | 1993-06-01 | Merck & Co., Inc. | 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof |
| US5210235A (en) * | 1992-08-26 | 1993-05-11 | Merck & Co., Inc. | Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics |
| US5332807A (en) * | 1993-04-14 | 1994-07-26 | Merck & Co., Inc. | Process of producing 8A- and 9A-azalide antibiotics |
| CN1034734C (zh) * | 1993-12-10 | 1997-04-30 | 北京市集才药物研究所 | 一种新的阿齐红霉素结晶及其制备方法 |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| JP2977907B2 (ja) | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | アジスロマイシンの放出調節された剤形 |
| ES2122905B1 (es) * | 1996-07-11 | 1999-11-16 | Astur Pharma Sa | Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato). |
| WO1999020639A2 (en) * | 1997-10-16 | 1999-04-29 | Pliva, Farmaceutska Industrija ,Dionicko, Drustvo | NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES |
| US6861411B1 (en) | 1997-12-02 | 2005-03-01 | Pfizer, Inc. | Method of treating eye infections with azithromycin |
| PT102130A (pt) * | 1998-03-13 | 1999-09-30 | Hovione Sociedade Quimica S A | Processo de preparacao de dihidrato de azitromicina |
| TW546302B (en) | 1998-05-08 | 2003-08-11 | Biochemie Sa | Improvements in macrolide production |
| US6245903B1 (en) | 1998-08-21 | 2001-06-12 | Apotex, Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
| WO2000032203A1 (en) * | 1998-11-30 | 2000-06-08 | Teva Pharmaceutical Industries Ltd. | Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
| US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| ATE392427T1 (de) * | 1999-05-18 | 2008-05-15 | Pfizer Prod Inc | Neue kristalline formen eines macrolidantibiotikums |
| ES2267549T3 (es) | 1999-06-29 | 2007-03-16 | Sandoz Ag | Procedimiento para la produccion de azitromicina. |
| ES2177373B1 (es) * | 1999-11-26 | 2003-11-01 | Astur Pharma Sa | Preparacion de azitromicina en su forma no cristalina |
| ATE388159T1 (de) | 2000-01-04 | 2008-03-15 | Teva Pharma | Verfahren zur herstellung von azithromycin- dihydrat |
| ES2162764B1 (es) * | 2000-05-17 | 2003-04-01 | Ercros Ind Sa | Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion. |
| CA2417353C (en) | 2000-07-25 | 2009-09-01 | Laboratorio Silanes,S.A. De C.V. | Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-one, and obtaining a new form of 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a |
| ES2172417B1 (es) * | 2000-07-31 | 2003-09-16 | Sint Quimica Sa | Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden. |
| CA2419873A1 (en) | 2000-08-23 | 2002-02-28 | Wockhardt Limited | Process for preparation of anhydrous azithromycin |
| CN100341886C (zh) * | 2000-11-27 | 2007-10-10 | 桑多斯股份公司 | 大环内酯类化合物的溶剂化物 |
| HU229488B1 (hu) * | 2000-11-27 | 2014-01-28 | Sandoz Ag | Eljárás makrolid hidrátok elõállítására |
| IN190080B (cg-RX-API-DMAC7.html) * | 2001-01-29 | 2003-06-07 | Alembic Ltd | |
| KR100491183B1 (ko) | 2001-03-21 | 2005-05-25 | 한미약품 주식회사 | 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물 |
| EP1652851A1 (en) | 2001-05-22 | 2006-05-03 | Pfizer Products Inc. | New crystal form of Azithromycin |
| JP2004530703A (ja) * | 2001-05-22 | 2004-10-07 | ファイザー・プロダクツ・インク | 結晶形アジスロマイシン |
| US6861413B2 (en) | 2001-05-22 | 2005-03-01 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| JP2005501862A (ja) * | 2001-08-21 | 2005-01-20 | ファイザー・プロダクツ・インク | １回限りの投与量のアジスロマイシン |
| BR0215193A (pt) * | 2001-12-21 | 2004-11-16 | Pfizer Prod Inc | Formulações de azitromicina diretamente compressìveis |
| KR100669279B1 (ko) * | 2001-12-21 | 2007-01-16 | 화이자 프로덕츠 인크. | 아지트로마이신의 습식 제립 방법 |
| EP1478347A1 (en) * | 2002-02-01 | 2004-11-24 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
| US7376064B2 (en) | 2002-02-25 | 2008-05-20 | Samsung Electronics Co., Ltd. | Method and apparatus for recording data on optical recording medium |
| ITMI20021209A1 (it) * | 2002-06-04 | 2003-12-04 | Chemi Spa | Processo di preparazione di azitromicina ad elevata purezza |
| US6855813B2 (en) * | 2002-07-19 | 2005-02-15 | Alembic Limited | Process for the preparation of azithromycin monohydrate |
| HRP20020614A2 (en) | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
| GB2395482A (en) * | 2003-07-03 | 2004-05-26 | Jubilant Organosys Ltd | Process for preparing non-hygroscopic azithromycin dihydrate |
| US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
| WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
| BRPI0417360A (pt) * | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | método para a preparação de multiparticulados farmacêuticos |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| AU2004294818A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Azithromycin multiparticulate dosage forms by liquid-based processes |
| JP2007513147A (ja) * | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法 |
| CN1889931A (zh) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法 |
| WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| JP2007513139A (ja) * | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 安定性の改善した多粒子組成物 |
| RU2260012C1 (ru) * | 2004-01-29 | 2005-09-10 | Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" | Способ кристаллизации азитромицина дигидрата |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| WO2006011160A1 (en) | 2004-06-28 | 2006-02-02 | Alembic Limited | Process for the preparation of azithromycin monohydrate isopropanol clathrate |
| CN1308361C (zh) * | 2004-08-09 | 2007-04-04 | 大连振邦氟涂料股份有限公司 | 乙烯－三氟氯乙烯共聚物的制备方法 |
| US7683162B2 (en) * | 2004-08-30 | 2010-03-23 | Taro Pharmaceutical Industries Limited | Process of preparing a crystalline azithromycin monohydrate |
| DE602005021684D1 (de) * | 2004-12-01 | 2010-07-15 | Teva Gyogyszergyar Zartkoeruen | Verfahren zur herstellung von pimecrolimus |
| WO2006067576A1 (en) * | 2004-12-21 | 2006-06-29 | Pfizer Products Inc. | Enteric coated azithromycin multiparticulates |
| US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| CN100366686C (zh) * | 2006-01-12 | 2008-02-06 | 济南瑞氟化工科技有限公司 | 一种氟硅超双疏不粘涂料 |
| AU2007256844A1 (en) * | 2006-06-05 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted erythromycin analogs |
| US7704959B2 (en) | 2006-10-03 | 2010-04-27 | Dow Pharmaceutical Sciences | Azithromycin for the treatment of nodular acne |
| US20090062220A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched azithromycin |
| CN101177441B (zh) * | 2007-12-05 | 2012-05-23 | 浙江耐司康药业有限公司 | 一种稳定的阿奇霉素一水合物结晶的制备方法 |
| CN101624412B (zh) * | 2008-07-10 | 2012-07-04 | 刘力 | 大环内酯类衍生物及其制备和用途 |
| US8629139B2 (en) | 2008-10-07 | 2014-01-14 | Mpex Pharmaceuticals, Inc. | Topical use of Levofloxacin for reducing lung inflammation |
| HUE038428T2 (hu) | 2008-10-07 | 2018-10-29 | Horizon Orphan Llc | Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében |
| CN101418026B (zh) * | 2008-10-09 | 2011-05-18 | 南京工业大学 | 一种晶型和粒度可控的阿奇霉素结晶工艺 |
| CN101787063B (zh) * | 2009-01-23 | 2012-12-19 | 刘力 | 抗感染药物及其制备和用途 |
| CN102413826A (zh) | 2009-03-13 | 2012-04-11 | 达·沃尔泰拉公司 | 用于消除革兰氏阴性菌的组合物和方法 |
| ES2739979T3 (es) | 2009-09-04 | 2020-02-05 | Horizon Orphan Llc | Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística |
| CN102911219A (zh) * | 2011-08-03 | 2013-02-06 | 山东方明药业集团股份有限公司 | 一种阿齐霉素在水相直接结晶的方法 |
| CN103159811A (zh) * | 2011-12-10 | 2013-06-19 | 山东方明药业集团股份有限公司 | 一种阿齐霉素中间体9a-脱氧-9a-氮杂-9a-高红霉素A的制备方法 |
| WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
| CN102417531B (zh) * | 2011-12-20 | 2014-06-11 | 浙江国邦药业有限公司 | 一种阿奇霉素一水合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4020270A (en) * | 1974-05-02 | 1977-04-26 | Societa' Farmaceutici Italia S.P.A. | L-lyxohex-1-enopyranose derivative |
| US4219641A (en) * | 1979-06-14 | 1980-08-26 | The Upjohn Company | Process for preparing erythromycin succinate |
| YU43006B (en) | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| PH19293A (en) * | 1982-11-15 | 1986-03-04 | Pfizer | Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof |
| US4526889A (en) * | 1982-11-15 | 1985-07-02 | Pfizer Inc. | Epimeric azahomoerythromycin A derivative, intermediates and method of use |
| US4512982A (en) * | 1984-04-13 | 1985-04-23 | Pfizer Inc. | 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method |
| YU43402B (en) * | 1985-03-04 | 1989-06-30 | Pliva Pharm & Chem Works | Process for preparation of 11-aza-10-deoxo-10-dihydroeritromycin "a" by using electro-chemical reduction |
| WO1989002271A1 (en) | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
-
1987
- 1987-07-09 WO PCT/US1987/001612 patent/WO1989000576A1/en not_active Ceased
- 1987-07-09 MX MX1221388A patent/MX12213A/es unknown
- 1987-07-09 RO RO143593A patent/RO107257B1/ro unknown
- 1987-07-09 RU SU874742955A patent/RU2066324C1/ru active
- 1987-07-09 UA UA93004522A patent/UA27040C2/uk unknown
-
1988
- 1988-05-11 IN IN418/DEL/88A patent/IN168879B/en unknown
- 1988-06-15 AP APAP/P/1988/000093A patent/AP44A/en active
- 1988-06-28 AT AT88305921T patent/ATE72446T1/de not_active IP Right Cessation
- 1988-06-28 EP EP88305921A patent/EP0298650B1/en not_active Expired - Lifetime
- 1988-06-28 ES ES198888305921T patent/ES2038756T3/es not_active Expired - Lifetime
- 1988-06-28 DE DE8888305921T patent/DE3868296D1/de not_active Expired - Lifetime
- 1988-07-04 IL IL86979A patent/IL86979A/xx not_active IP Right Cessation
- 1988-07-05 BG BG084783A patent/BG47348A3/xx unknown
- 1988-07-05 MY MYPI88000744A patent/MY103744A/en unknown
- 1988-07-06 CS CS884896A patent/CS272241B2/cs not_active IP Right Cessation
- 1988-07-06 JP JP63168637A patent/JPH0631300B2/ja not_active Expired - Lifetime
- 1988-07-07 PL PL1988273590A patent/PL157145B1/pl unknown
- 1988-07-07 EG EG376/88A patent/EG18527A/xx active
- 1988-07-07 DD DD88317672A patent/DD271705A5/de unknown
- 1988-07-07 PH PH37189A patent/PH30953A/en unknown
- 1988-07-07 PT PT87933A patent/PT87933B/pt not_active IP Right Cessation
- 1988-07-07 IS IS3370A patent/IS1540B/is unknown
- 1988-07-07 AR AR88311356A patent/AR243532A1/es active
- 1988-07-07 CA CA000571381A patent/CA1314876C/en not_active Expired - Lifetime
- 1988-07-08 ZA ZA884925A patent/ZA884925B/xx unknown
- 1988-07-08 IE IE210888A patent/IE60354B1/en not_active IP Right Cessation
- 1988-07-08 AU AU18839/88A patent/AU604553B2/en not_active Expired
- 1988-07-08 NZ NZ225338A patent/NZ225338A/xx unknown
- 1988-07-08 SI SI8811325A patent/SI8811325A8/sl unknown
- 1988-07-08 YU YU1325/88A patent/YU45075B/xx unknown
- 1988-07-08 OA OA59384A patent/OA08743A/xx unknown
- 1988-07-08 KR KR1019880008463A patent/KR900006218B1/ko not_active Expired
- 1988-07-08 DK DK198803806A patent/DK172573B1/da not_active IP Right Cessation
- 1988-07-08 CN CN88104331A patent/CN1016785B/zh not_active Expired
- 1988-07-11 MA MA21565A patent/MA21323A1/fr unknown
-
1990
- 1990-01-08 NO NO90900077A patent/NO171556C/no not_active IP Right Cessation
- 1990-01-08 FI FI900087A patent/FI91263C/fi not_active IP Right Cessation
-
1992
- 1992-02-06 GR GR920400067T patent/GR3003737T3/el unknown
- 1992-12-21 US US07/994,040 patent/US6268489B1/en not_active Expired - Lifetime
-
1993
- 1993-11-17 LV LVP-93-1240A patent/LV10624B/xx unknown
-
1994
- 1994-02-22 SG SG27794A patent/SG27794G/en unknown
- 1994-11-17 HK HK127594A patent/HK127594A/en not_active IP Right Cessation
-
1995
- 1995-06-30 HU HU95P/P00738P patent/HU211862A9/hu unknown
- 1995-10-20 CY CY177695A patent/CY1776A/xx unknown
-
1998
- 1998-03-30 BA BA980213A patent/BA98213B1/bs active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT87933B (pt) | Processo para a preparacao de di-hidrato de azitromicina | |
| KR850000964B1 (ko) | 에리트로마이신a의 옥심 유도체류의 제조방법 | |
| JPH053476B2 (cg-RX-API-DMAC7.html) | ||
| HU186845B (en) | Process for producing new erythromycin compounds and pharmaceutical compositions containing them as active agents | |
| CS220790B2 (en) | Method of separation of the -6-methoxy-alpha-methyl-2-naphtalene vinegar acid from the mixtures of the a/-/-6-methoxy-alpha-methyl-2/naphtalene vinegar acid or salts thereof | |
| JP3030780B2 (ja) | 光学活性なケテンジチオアセタール誘導体及びその製造方法 | |
| JPS6247196B2 (cg-RX-API-DMAC7.html) | ||
| JPS6360031B2 (cg-RX-API-DMAC7.html) | ||
| KR100375957B1 (ko) | D4t 동질이상 i 형의 제조방법 | |
| US4115439A (en) | Process for the preparation of optically active α-phenylglycine and intermediates thereof | |
| JPS593476B2 (ja) | 光学活性クロルフエニラミン・アシルフエニルグリシン塩及びその製造法 | |
| US4048158A (en) | d-α-Isobutylsulfobenzylpenicillin hemi-solvate crystals | |
| JPH06340599A (ja) | 光学活性２−アミノ酪酸の製法 | |
| KR880001235B1 (ko) | 결정성 무수 소듐 19-데옥시아글리콘 디아네마이신의 제조 방법 | |
| HU203763B (en) | Process for producing azitromycin-dihydrate | |
| JP2003518133A (ja) | ９−デオキソ−９（ｚ）−ヒドロキシイミノエリスロマイシンａを製造、単離する方法 | |
| JPS591702B2 (ja) | 光学活性トリプトフアン・ｐ−フエノ−ルスルホン酸塩の製法 | |
| US2999111A (en) | Recovery of 6-deoxy-6-demethyltetracycline | |
| US1931123A (en) | Method of isolating alpha-aryl-beta-aminoethanols and compound so obtained | |
| US4282349A (en) | Crystalline ribofuranosyl halides and other derivatives and methods for producing same | |
| US6051695A (en) | Process for preparing erythromycin derivative, such as roxithromycin, from the corresponding oxime | |
| JPH0259817B2 (cg-RX-API-DMAC7.html) | ||
| PT96694B (pt) | Processo para a preparacao de derivados de pirimidinatriona | |
| JPH023627A (ja) | 光学活性１−メチル−３−フェニルプロピルアミンの製造法 | |
| JPS60166650A (ja) | アシルアミノ−ナフタレン誘導体の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG3A | Patent granted, date of granting |
Effective date: 19940316 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20090316 |